Mid-Atlantic BioTherapeutics is thrilled to announce the acquisition of XPose Therapeutics, a transformative milestone that expands our oncology pipeline and accelerates our mission to deliver breakthrough therapies to patients in need. XPose brings cutting-edge expertise in targeting “undruggable” DNA Damage Response (DDR) proteins for cancer treatment, perfectly complementing MABT’s immunotherapy platform and commitment to precision oncology.
With the addition of XPose’s world-class scientific team—including renowned experts Dr. Debanu Das and Dr. Matthew Duncton—and their innovative small molecule programs directed against challenging cancer targets, we are positioned to accelerate the development of next-generation therapeutics for ovarian, breast, lung, and brain cancers. This acquisition strengthens our integrated approach to addressing unmet medical needs across oncology and neurological diseases, bringing us closer to our vision of transforming lives through compassionate innovation. Together, we’re advancing a new era of hope for patients facing some of the most difficult-to-treat cancers.
Please stay tuned for more updates as we complete the XPose integration and accelerate the development of these important programs.